Our mission is to make radioligand therapy applicable to more cancers, available to more people, thereby improving the lives of cancer patients and their families everywhere.
In early 2017 Dr. Neil Fleshner, a practicing urologist in Toronto, sent his first prostate cancer patient for an experimental new cancer treatment - Radioligand Therapy. The treatment was not available anywhere in North America – Dr. Fleshner’s patient had to travel to Germany, at significant personal expense, for it to be administered. Wanting to improve patient access to these advancements in cancer care, Dr. Fleshner began thinking about how a team could be assembled to build the infrastructure necessary to bring these innovative therapeutics to more people.
This seed of an idea resulted in the formation of POINT Biopharma.
POINT Biopharma is a clinical-stage global pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. In addition to our exciting pipeline of radioligand molecules for a variety of cancers, we also operate our radiopharmaceutical production facility in Indianapolis, Indiana which is capable of servicing all of North America as well as many global locations.
Dr. McCann has overall responsibility for the day-to-day operations of POINT. Prior to taking on this role, Dr. McCann was CEO of Centre for Probe Development and Commercialization (CPDC) where he led the organization through development and validation of 17 different imaging probe and radiotherapeutic programs, used in national and international clinical trials. Prior to joining CPDC, Dr. McCann was a Scientist in Pharmaceutical Development at GlaxoSmithKline, responsible for developing products across all stages of clinical development.
Dr. McCann has a Ph.D. in biochemistry from McMaster University.
Bill is responsible for all planning, implementation management and operation of all the financial activities of POINT. Previously a senior partner at EY, Bill has over 37 years of professional experience involving a wide range of high-growth companies in the pharmaceutical, manufacturing, and technology sectors, including private and publicly traded Canadian and US NASDAQ listed companies.
Michael is responsible for commercial operations, market strategy and patient focused engagement. Prior to joining, Michael spent 7 years at Sanofi Genzyme Canada leading Commercial Operations, Patient infusions and support programs, Strategy, Finance, and most recently as the Rare Disease Franchise Head responsible for sales and marketing across a broad portfolio of orphan drug and oncology products. While in this role, Michael led teams responsible for physician and patient engagement, market access, and pricing.
Michael is a Chartered accountant and CPA.
Dr. Neil Fleshner graduated with a medical degree from the University of Toronto in 1988. He completed specialty training in urologic surgery and oncology from 1993 to 1996, received a Master’s in Public Health in epidemiology from Columbia University in 1997, and completed his oncology training at Memorial Sloan-Kettering Cancer Center.
Dr. Fleshner is certified in both urology and epidemiology. Dr. Fleshner is also a Professor of Surgery at the University of Toronto. In the past, he has served as the Head of the Division of Urology at the University Health Network, and the Head of Genitourinary Cancer Site group at the Princess Margaret Hospital. He also holds the prestigious Love Chair in prostate cancer prevention at Princess Margaret Hospital.
Todd is responsible for the US manufacturing operations for POINT. Prior to taking on this role, Todd led the construction and operations of a full-scale commercial radiopharmaceutical manufacturing facility at Radiomedix and was previously head of Zevacor’s quality and regulatory affairs team. An industrial engineer, with operations and manufacturing expertise spanning over 25 years, Todd has significant expertise in radiopharmaceutical manufacturing, quality systems and regulatory affairs.
Jessica brings over 15 years of experience developing early and late stage oncology drugs. She joins POINT from Progenics Pharmaceuticals where she served as SVP clinical development advancing their PSMA targeted diagnostic and radiotherapeutic portfolio in prostate cancer and their radiotherapeutic neuroendocrine program which led to the approval of AZEDRA®. Previously, Jessica advanced global immunotherapy programs at the Ludwig Institute for Cancer Research, an orphan drug program at Gentium SpA, now Jazz Pharmaceuticals, and supported the development of a CRO business unit at US Oncology. She has an expertise in study design and execution, has directly led regulatory agency communications and FDA inspections, and the clinical submission of several INDs and NDAs. Jessica started her career in the pharmaceutical industry as a Statistical Programmer and Biostatistician after receiving a Master of Public Health in Epidemiology & Biostatistics at the George Washington University.
Allan C. Silber is the Chairman of Point Biopharma. He is also chairman of Verity Pharmaceuticals, a specialty pharmaceutical company and also chairs Heritage Global Inc., a global financial services and asset trading company providing corporate and financial asset monetization, advisory, and valuation services. Mr. Silber has an extensive background in the private equity, real-estate and financial services fields. Mr. Silber is the former CEO of Street Capital Group Inc. and Counsel Corporation.
Howard brings over twenty years of Canadian and U.S. corporate pharmaceutical senior commercial management experience to POINT and is the CEO of Verity Pharmaceuticals. Howard has also gained experience as a CEO within the medical market research and scientific communications industries.
Howard acquired corporate pharmaceutical brand experiences include the launch of Cipro in Canada and Cipro IV for global markets. Additionally, Howard launched Cardizem CD in Canada and moved to the national commercial team in the USA (Sanofi) on the cardiovascular portfolio, with national responsibilities on Cardizem CD ($1.3 billion in sales) and led the launch of Teczem (Co-promoted with Merck) in the American hypertension market.